In 17 heavily pretreated NSCLC EGFR mutant (EGFR mut) patients the combination shows an ORR of 24% and a DCR of 71%; tumor ...

Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that ...

With tumor reduction seen in 48% of the 33 patients studied, the combination treatment had an overall response rate of 21% in ...

Merck said on Monday it has discontinued the development of two experimental cancer drugs after their failure in several ...

Researchers have used a chemical compound to light up treatment-resistant cancers on imaging scans, in a breakthrough that could help medical professionals better target and treat cancer.

The FDA granted breakthrough therapy designation to sacituzumab govitecan for patients with ES-SCLC progressing on platinum ...

The US regulator has turned down J&J's marketing application for a subcutaneous (SC) formulation of EGFRxMET bispecific ...

The KEYTRUDA regimen improved event-free survival (EFS) by 42%, indicating a lower risk of disease progression ... journey of ...

The U.S. Food and Drug Administration has declined to approve an injectable version of Johnson & Johnson's drug Rybrevant for ...

Merck & Co Inc (NYSE:MRK) revealed that it would discontinue the clinical development programs for vibostolimab and ...

Among the heavily pretreated NSCLC EGFR wild-type patients, the combination therapy demonstrated an overall response rate of 21 percent, and a disease control rate of 76 percent. Moreover, tumor ...

PanCAN Chief Scientific & Medical Officer Dr. Anna Berkenblit looks back on the progress made toward better understanding and ...